Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives $177.00 Average Target Price from Brokerages

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has earned a consensus rating of “Moderate Buy” from the fifteen research firms that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $177.00.

A number of brokerages have recently commented on JAZZ. Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $140.00 to $175.00 in a report on Thursday, December 12th. TD Cowen dropped their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Piper Sandler reissued an “overweight” rating and issued a $163.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $207.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $125.05 on Tuesday. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The stock has a fifty day moving average of $122.74 and a 200 day moving average of $115.83. The firm has a market capitalization of $7.56 billion, a price-to-earnings ratio of 17.61, a PEG ratio of 0.87 and a beta of 0.56. Jazz Pharmaceuticals has a 52 week low of $99.06 and a 52 week high of $134.17.

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the sale, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. This represents a 10.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the transaction, the chief executive officer now directly owns 425,525 shares in the company, valued at $52,522,550.75. This represents a 0.35 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 7,253 shares of company stock worth $890,594 in the last 90 days. 4.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. UMB Bank n.a. boosted its stake in shares of Jazz Pharmaceuticals by 70.9% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after acquiring an additional 129 shares during the period. GAMMA Investing LLC raised its position in shares of Jazz Pharmaceuticals by 41.3% during the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 121 shares during the last quarter. Itau Unibanco Holding S.A. lifted its holdings in shares of Jazz Pharmaceuticals by 63.2% in the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock worth $49,000 after buying an additional 172 shares in the last quarter. Venturi Wealth Management LLC boosted its position in shares of Jazz Pharmaceuticals by 577.0% during the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after acquiring an additional 704 shares during the last quarter. Finally, Versant Capital Management Inc grew its stake in Jazz Pharmaceuticals by 56.7% during the fourth quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock valued at $119,000 after acquiring an additional 350 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.